INDUSTRY × Lymphoma, Large-Cell, Immunoblastic × Clear all
NCT00002663 2023-02-13

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Atara Biotherapeutics

Phase 1/2 Completed
58 enrolled 18 charts
NCT00003056 2021-05-06

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

Takeda

Phase 3 Terminated
105 enrolled
NCT00082823 2016-06-03

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Regeneron Pharmaceuticals

Phase 1 Completed
25 enrolled
NCT00083213 2016-06-03

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Regeneron Pharmaceuticals

Phase 1 Completed
25 enrolled
NCT01748721 2016-01-08

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Morphotek

Phase 1 Completed
27 enrolled
NCT00891137 2014-10-27

Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy

Cellerant Therapeutics

Phase 1 Completed
30 enrolled
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts
NCT00006368 2013-05-01

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Novartis

Phase 1 Completed
60 enrolled